The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

The present invention relates to foam. In particular, the present invention relates to profiled foams and processes for profiling absorbent foam products. More particularly, the present invention relates to processes for producing a profiled absorbent polyurethane foam product, comprising the steps of foaming, curing, profiling and drying, wherein profiling occurs before drying; and absorbent aliphatic polyurethane foam products having at least one profiled surface.

A dermal skin protectant and carrier comprising a combination of two different viscosity dimethicone components, wherein the difference between the two different viscosity dimethicone components is about 2.0 million cP or greater; and comprising at least one active ingredient.

The present disclosure provides pharmaceutical compositions comprising mometasone and diisopropyl adipate (DIPA) for topical administration. These compositions can be formulated as creams, lotions, and foams, and are particularly suitable for administration in hairy skin; for example, for treating inflammatory skin conditions, such as dermatitis, eczema, and psoriasis.

One larger [1] and one smaller tube [2], forming a functional unit with the smaller tube [2] positioned within the larger tube [1], both tubes are relocatable and demountable, both tubes with an aperture [3 and 4] at both ends, at least one aperture [5] being provided in the wall of the outer tube located at a distance of about between 1 mm and 10 cm from the tip [6], or several apertures positioned in a segment of 1-250 mm from the tip, wherein the diameter of the single aperture is between 70% and 120% of the inner diameter of the outer tube [1], or in case of several apertures, for each aperture 30-60% of the inner diameter of the outer tube, wherein the outer diameter of the inner tube is between 0.6 mm and 2.0 mm (F2 to F6), the outer diameter of the outer tube is between 1.3 mm and 3.6 mm (F4 to F11), and the distance between the outer wall of the inner tube and the inner wall of the outer tube is between 0.1 mm to 3.0 mm.

Provided herein is a topical composition comprising tapinarof and methods of treatment of cutaneous adverse effects caused by oncological therapy with the tapinarof composition. The tapinarof compositions of this invention are useful for the treatment, prevention or amelioration of cutaneous and/or mucosal adverse effect caused by oncological therapy selected from chemotherapy, immunotherapy, radiation therapy, targeted therapy, hormone therapy and stem cell transplant therapy.

A medical device for making foam includes a syringe having a plunger for dispensing a liquid from a liquid dispensing port, and a mixing chamber including a mixing chamber inlet, a mixing chamber outlet, a liquid flow channel extending between the mixing chamber inlet and the mixing chamber outlet, and a gas inlet channel that intersects with the liquid flow channel. The system has a gas cartridge containing the gas, a first gas conduit connected with the syringe, and a second gas conduit connected with the gas inlet channel. An actuator is coupled with the gas cartridge for releasing the gas into the first and second gas conduits. The released gas in the first gas conduit forces the plunger toward the liquid dispensing port for dispensing the liquid from the liquid dispensing port and into the liquid flow channel while the released gas in the second gas conduit flows into the gas inlet channel of the mixing chamber for mixing with the liquid in the liquid flow channel.

Disclosed are improved devices, systems, methods and compositions containing therapeutic lipid monolayer stabilized gas microfoam(s) that can be applied to the skin after a treatment which “damages” or otherwise modifies one or more skin layers, which can improve a patient's recovery time, reduce swelling, scarification and/or callous formation, reduce skin sensitivity and/or lead to a more desirable appearance in a shorter period of time than existing skin treatments.

Compositions comprising melatonin and dimethyl sulfoxide are provided for topical administration to the neorectum for use in the alleviation of the symptoms of low anterior resection syndrome.

An aerosolization system includes a container that is configured to deliver a unit dosage of a liquid when squeezed a single time. The system also includes an aerosolizer that is constructed of a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator includes a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Further, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. The opening provides a liquid path to the rear face of the vibratable membrane.